--- title: "Amycretin | PepTracker Pro" url: https://peptrackerpro.com/peptides/amycretin description: "A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. Aliases NNC9204-1177 +1 more Evidence Medium Evidence Last Updated 2026-06-14 Reading Time 4 min ## What It Is Amycretin (now officially named zenagamtide by Novo Nordisk, NNC9204-1177) is a first-in-class unimolecular agonist that simultaneously activates both the glucagon-like peptide-1 (GLP-1) and amylin receptors, developed by Novo Nordisk. Unlike combination therapies, amycretin integrates both mechanisms into a single molecule and is being developed in both subcutaneous and oral formulations. Phase 2 data in type 2 diabetes (n=448, 36 weeks) showed significant results: subcutaneous amycretin achieved up to 14.5% weight loss with HbA1c reductions up to 1.5% (77.6% of participants reaching HbA1c <7%), while the oral formulation achieved dose-dependent weight loss up to 10.1% with HbA1c improvements up to 1.5%. In the Phase 1b/2a obesity trial (published in The Lancet 2025), subcutaneous amycretin achieved approximately 22% weight loss at 36 weeks with no plateau observed. In May 2026, Novo Nordisk expanded the pivotal amycretin program, planning Phase 3 development for type 2 diabetes in addition to the obesity Phase 3 REDEFINE programme that began enrolling in Q1 2026. An FDA filing is expected in late 2026 or early 2027, with a regulatory decision window opening in 2027–2028. The oral formulation is particularly significant, as it could provide dual-agonist efficacy without injections — a major convenience advantage in the competitive obesity market. At the ADA 2026 Scientific Sessions (June 7, New Orleans), Novo Nordisk presented full Phase 2 dose-finding data for zenagamtide in type 2 diabetes — the first randomized controlled evidence of the compound's glycemic efficacy. The 36-week trial randomized 262 adults with type 2 diabetes inadequately controlled on metformin (±SGLT2 inhibitor, A1C 7.0–10.0%) to six doses of subcutaneous zenagamtide (0.4–40 mg once-weekly) or placebo. The 40 mg dose achieved 14.6% mean weight loss and a 1.71 percentage-point reduction in HbA1c — with 89% of participants at the 40 mg dose reaching the ADA's general A1C target of below 7%, and 77.8% achieving ≤6.5%. All doses met the primary endpoint of A1C reduction; weight reduction endpoints were met at doses ≥1.5 mg. Novo Nordisk confirmed plans to initiate a Phase 3 development program for zenagamtide in type 2 diabetes in H2 2026, in addition to the obesity Phase 3 REDEFINE programme already enrolling. The ADA 2026 T2D data establish zenagamtide as the only unimolecular GLP-1/amylin agonist with Phase 2 evidence across both obesity (22% weight loss, Lancet 2025) and type 2 diabetes populations. Also known as: NNC9204-1177, Zenagamtide ## Regulatory Status Investigational — Phase 3 Phase 3 REDEFINE programme enrolling for obesity (Q1 2026). Phase 3 for type 2 diabetes initiating H2 2026 (confirmed at ADA 2026, June 7). Phase 2 T2D data (ADA 2026): 14.6% weight loss + HbA1c −1.71% at 40 mg. FDA filing expected late 2026–early 2027. Effective: Q1 2026 View FDA Source (https://www.novonordisk.com/science-and-technology/r-d-pipeline.html) ## Why Researchers Study It Amycretin is notable as the first unimolecular GLP-1/amylin dual agonist, combining two complementary appetite-suppression pathways in a single molecule. The availability of both injectable and oral formulations provides flexibility. Its 22% weight loss at 36 weeks in early studies rivals the best results from GLP-1-only drugs, and the amylin component may offer unique satiety benefits through hypothalamic and area postrema signaling. ## Proposed Mechanisms - GLP-1 receptor agonism suppresses appetite, slows gastric emptying, and enhances insulin secretion - Amylin receptor activation promotes satiety through hypothalamus and area postrema signaling - Dual receptor engagement in a single molecule provides complementary appetite suppression - Slows gastric emptying through both GLP-1 and amylin pathways - Improves glycemic control through enhanced insulin sensitivity and secretion ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Human (Phase 1b/2a) | Weekly SC amycretin in adults with overweight/obesity, 36 weeks (Lancet 2025) | 22% weight loss with subcutaneous formulation; 13.1% with oral in 12 weeks | Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract | | Human (Phase 2) | SC and oral amycretin in T2D on metformin ± SGLT2i, 36 weeks (n=448) | Up to 14.5% weight loss (SC); HbA1c reduction up to 1.8 pp; 89.1% achieving HbA1c <7% | Source: https://www.globenewswire.com/news-release/2025/11/25/3194155/0/en/Novo-Nordisk-phase-2-trial-with-amycretin-reports-significant-weight-loss-and-HbA1c-reduction-in-type-2-diabetes.html | | Human (Phase 3) | Obesity/overweight program initiated Q1 2026; T2D program planned | Enrolling; results expected 2028–2029 | Source: https://www.novonordisk.com/science-and-technology/r-d-pipeline.html | | Human (Phase 2, T2D dose-finding — ADA 2026, June 7) | Adults with T2D on metformin ± SGLT2i (n=262, A1C 7.0–10.0%), 6 doses (0.4–40 mg SC once-weekly) vs placebo, 36 weeks | 40 mg: 14.6% weight loss, HbA1c −1.71%, 89% achieved A1C <7%, 77.8% achieved ≤6.5%; all doses met primary A1C endpoint; weight endpoint met at doses ≥1.5 mg; Phase 3 T2D program planned H2 2026 | Source: https://www.prnewswire.com/news-releases/novo-nordisks-investigational-zenagamtide-shows-significant-a1c-reductions-with-up-to-14-6-weight-loss-in-adults-with-type-2-diabetespresented-at-ada-2026--302793124.html | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Researching Amycretin? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=amycretin) ## Safety & Cautions - Phase 3 trials have just begun; no pivotal efficacy data yet - Gastrointestinal side effects (nausea, vomiting) consistent with incretin and amylin class - Long-term safety and efficacy beyond 36 weeks not yet established - Oral formulation tolerability at higher doses needs Phase 3 confirmation - Only available through clinical trial enrollment ## Comparisons See how Amycretin compares to related peptides: Amycretin vs ACCG-2671: https://peptrackerpro.com/compare/amycretin-vs-accg-2671 Amycretin vs ALV-200: https://peptrackerpro.com/compare/amycretin-vs-alv-200 Amycretin vs ASC39: https://peptrackerpro.com/compare/amycretin-vs-asc39 Amycretin vs Cagrilintide: https://peptrackerpro.com/compare/amycretin-vs-cagrilintide Amycretin vs Eloralintide: https://peptrackerpro.com/compare/amycretin-vs-eloralintide Amycretin vs Maridebart Cafraglutide (MariTide): https://peptrackerpro.com/compare/amycretin-vs-maridebart-cafraglutide Amycretin vs MET-233i: https://peptrackerpro.com/compare/amycretin-vs-met-233i Amycretin vs Semaglutide: https://peptrackerpro.com/compare/amycretin-vs-semaglutide Amycretin vs Tirzepatide: https://peptrackerpro.com/compare/amycretin-vs-tirzepatide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Amycretin Phase 1b/2a SC results — The Lancet 2025 PubMed (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract) 2. [2] Novo Nordisk — Phase 2 T2D trial results, November 2025 PubMed (https://www.globenewswire.com/news-release/2025/11/25/3194155/0/en/Novo-Nordisk-phase-2-trial-with-amycretin-reports-significant-weight-loss-and-HbA1c-reduction-in-type-2-diabetes.html) 3. [3] Novo Nordisk advances amycretin to Phase III — Clinical Trials Arena 2026 PubMed (https://www.clinicaltrialsarena.com/news/novo-nordisk-obesity-drug-phase-iii-trial-advance/) 4. [4] Novo Nordisk expands pivotal amycretin program — Fierce Biotech 2026 PubMed (https://www.fiercebiotech.com/biotech/novo-nordisk-expands-pivotal-amycretin-program-after-dual-agonist-shines-diabetes) 5. [5] Amycretin, a novel unimolecular GLP-1 and amylin receptor agonist: results from a phase 1b/2a RCT — The Lancet 2026 PubMed (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract) 6. [6] Novo Nordisk — Zenagamtide Phase 2 T2D Data Presented at ADA 2026 (June 7, 2026) PubMed (https://www.prnewswire.com/news-releases/novo-nordisks-investigational-zenagamtide-shows-significant-a1c-reductions-with-up-to-14-6-weight-loss-in-adults-with-type-2-diabetespresented-at-ada-2026--302793124.html) 7. [7] Zenagamtide Achieves 89% A1C Target with 14.6% Weight Loss in Diabetes Trial — Clinical Trial Vanguard PubMed (https://www.clinicaltrialvanguard.com/news/zenagamtide-achieves-89-a1c-target-with-14-6-weight-loss-in-diabetes-trial/) ### Keep researching in the app - Log Amycretin to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=amycretin Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### ACCG-2671 Low Evidence An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/accg-2671 \+ Compare: https://peptrackerpro.com/compare?select=accg-2671 Track in App: https://app.peptrackerpro.com/?add=accg-2671 ### ALV-200 Low Evidence ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/alv-200 \+ Compare: https://peptrackerpro.com/compare?select=alv-200 Track in App: https://app.peptrackerpro.com/?add=alv-200 ### ASC39 Low Evidence ASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026. View Details: https://peptrackerpro.com/peptides/asc39 \+ Compare: https://peptrackerpro.com/compare?select=asc39 Track in App: https://app.peptrackerpro.com/?add=asc39 ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### Eloralintide Medium Evidence A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/eloralintide \+ Compare: https://peptrackerpro.com/compare?select=eloralintide Track in App: https://app.peptrackerpro.com/?add=eloralintide ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/maridebart-cafraglutide \+ Compare: https://peptrackerpro.com/compare?select=maridebart-cafraglutide Track in App: https://app.peptrackerpro.com/?add=maridebart-cafraglutide ### MET-233i Medium Evidence MET-233i is a first-in-class, once-monthly ultra-long-acting amylin analog for obesity, originally developed by Metsera and now a Pfizer asset. In its Phase 1 trial it produced up to 8.4% placebo-subtracted weight loss after five weekly doses and showed a roughly 19-day half-life - the most durable of any reported amylin analog - supporting once-monthly subcutaneous dosing. It is engineered to be combined with Metsera's monthly GLP-1 agonist MET-097i in a single once-monthly injection. View Details: https://peptrackerpro.com/peptides/met-233i \+ Compare: https://peptrackerpro.com/compare?select=met-233i Track in App: https://app.peptrackerpro.com/?add=met-233i ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Amycretin", "description": "A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a.", "url": "https://peptrackerpro.com/peptides/amycretin", "lastReviewed": "2026-06-14", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Amycretin", "item": "https://peptrackerpro.com/peptides/amycretin" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following Novo Nordisk's obesity pipeline beyond semaglutide?", "acceptedAnswer": { "@type": "Answer", "text": "Amycretin is a research peptide studied in preclinical models. A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a." } }, { "@type": "Question", "name": "Those interested in dual-mechanism weight loss drugs?", "acceptedAnswer": { "@type": "Answer", "text": "Amycretin is a research peptide studied in preclinical models. A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a." } }, { "@type": "Question", "name": "Individuals comparing injectable vs oral obesity therapies?", "acceptedAnswer": { "@type": "Answer", "text": "Amycretin is a research peptide studied in preclinical models. A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a." } }, { "@type": "Question", "name": "Researchers tracking amylin receptor agonist development?", "acceptedAnswer": { "@type": "Answer", "text": "Amycretin is a research peptide studied in preclinical models. A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a." } } ] } ] ```